70 related articles for article (PubMed ID: 25919760)
1.
Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
[TBL] [Abstract][Full Text] [Related]
2. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
Larrouy L; Chazallon C; Landman R; Capitant C; Peytavin G; Collin G; Charpentier C; Storto A; Pialoux G; Katlama C; Girard PM; Yeni P; Aboulker JP; Brun-Vezinet F; Descamps D;
Antimicrob Agents Chemother; 2010 Jul; 54(7):2910-9. PubMed ID: 20439606
[TBL] [Abstract][Full Text] [Related]
3. Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients.
Kapoor A; Shapiro B; Shafer RW; Shulman N; Rhee SY; Delwart EL
Retrovirology; 2008 Jan; 5():7. PubMed ID: 18221530
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous Mutations in HIV-1 Gag, Protease, RT p66 in the First Replication Cycle and How They Appear: Insights from an In Vitro Assay on Mutation Rates and Types.
Yeo JY; Koh DW; Yap P; Goh GR; Gan SK
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396460
[TBL] [Abstract][Full Text] [Related]
5. Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy.
Tzou PL; Rhee SY; Pond SLK; Manasa J; Shafer RW
Sci Data; 2018 Jul; 5():180147. PubMed ID: 30040081
[TBL] [Abstract][Full Text] [Related]
6. Genetic diversity in the partial sequence of the HIV-1 gag gene among people living with multidrug-resistant HIV-1 infection.
Alencar CS; Sabino EC; Diaz RS; Mendrone-Junior A; Nishiya AS
Rev Inst Med Trop Sao Paulo; 2024; 66():e35. PubMed ID: 38865573
[TBL] [Abstract][Full Text] [Related]
7. The impact of Gag non-cleavage site mutations on HIV-1 viral fitness from integrative modelling and simulations.
Samsudin F; Gan SK; Bond PJ
Comput Struct Biotechnol J; 2021; 19():330-342. PubMed ID: 33425260
[TBL] [Abstract][Full Text] [Related]
8. Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV.
Climaco-Arvizu S; Flores-López V; González-Torres C; Gaytán-Cervantes FJ; Hernández-García MC; Zárate-Segura PB; Chávez-Torres M; Tesoro-Cruz E; Pinto-Cardoso SM; Bekker-Méndez VC
BMC Infect Dis; 2022 May; 22(1):447. PubMed ID: 35538426
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Evolutionary Dynamics under Nonsuppressive Antiretroviral Therapy.
Kemp SA; Charles OJ; Derache A; Smidt W; Martin DP; Iwuji C; Adamson J; Govender K; de Oliveira T; Dabis F; Pillay D; Goldstein RA; Gupta RK
mBio; 2022 Jun; 13(3):e0026922. PubMed ID: 35446121
[TBL] [Abstract][Full Text] [Related]
10. Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria.
Datir R; El Bouzidi K; Dakum P; Ndembi N; Gupta RK
J Antimicrob Chemother; 2019 May; 74(5):1402-1407. PubMed ID: 30726945
[TBL] [Abstract][Full Text] [Related]
11. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.
Teto G; Tagny CT; Mbanya D; Fonsah JY; Fokam J; Nchindap E; Kenmogne L; Njamnshi AK; Kanmogne GD
Sci Rep; 2017 Oct; 7(1):14136. PubMed ID: 29074854
[TBL] [Abstract][Full Text] [Related]
12. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
Collier D; Iwuji C; Derache A; de Oliveira T; Okesola N; Calmy A; Dabis F; Pillay D; Gupta RK;
Clin Infect Dis; 2017 Apr; 64(8):1006-1016. PubMed ID: 28329393
[TBL] [Abstract][Full Text] [Related]
13. Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.
Sutherland KA; Collier DA; Claiborne DT; Prince JL; Deymier MJ; Goldstein RA; Hunter E; Gupta RK
Sci Rep; 2016 Nov; 6():38153. PubMed ID: 27901085
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
[TBL] [Abstract][Full Text] [Related]
15. Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
Sutherland KA; Parry CM; McCormick A; Kapaata A; Lyagoba F; Kaleebu P; Gilks CF; Goodall R; Spyer M; Kityo C; Pillay D; Gupta RK;
PLoS One; 2015; 10(9):e0137834. PubMed ID: 26382239
[TBL] [Abstract][Full Text] [Related]
16. Mutations Proximal to Sites of Autoproteolysis and the α-Helix That Co-evolve under Drug Pressure Modulate the Autoprocessing and Vitality of HIV-1 Protease.
Louis JM; Deshmukh L; Sayer JM; Aniana A; Clore GM
Biochemistry; 2015 Sep; 54(35):5414-24. PubMed ID: 26266692
[TBL] [Abstract][Full Text] [Related]
17. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
